TNG:EPA
Transgene SA
€0.72
arrow_downward
-1.23%(-0.0090) 1D
Nov 13, 5:35:21 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€0.73
High
€0.74
Low
€0.72
Mkt. cap
205.09M
Avg. vol.
91.02K
Volume
63.63K
52-wk high
€1.36
52-wk low
€0.67
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
Open
€0.73
High
€0.74
Low
€0.72
Mkt. cap
205.09M
Avg. vol.
91.02K
Volume
63.63K
52-wk high
€1.36
52-wk low
€0.67
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
News stories
From web sources and news partners
Yahoo Finance
·
20 hours ago
Stock market today: Dow, S&P 500, Nasdaq futures edge higher after wholesale inflation grows, Nvidia stock rebounds
CNBC
·
1 day ago
Nasdaq Composite slides as Nvidia shares tumble on Jensen Huang’s exit; oil prices jump
MarketWatch
·
12 hours ago
Stock Market on Nov. 13, 2026: Dow ends slightly higher, S&P 500 and Nasdaq fall as tech stocks struggle after Nvidia turmoil; U.S. equities market books weekly gain — live updates
Foreign Policy Journal
·
31 minutes ago
Centrus Energy (NYSE: LEU) Drops 45% In 90 Days Even As Meta-Backed Nuclear Contracts Roll In
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA
CEO-
Employees152
FoundedDec 1979
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitetransgene.com